Laboratory and clinical experience with keyhole limpet hemocyanin (immucothel®) in superficial bladder cancer

Journal fur Urologie und Urogynakologie

Volumn 10, Issue 2, 2003, Pages 18-21

  Lamm, Donald L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DOXORUBICIN; KEYHOLE LIMPET HEMOCYANIN; MITOMYCIN C; THIOTEPA;

ARTICLE; BCG VACCINATION; BLADDER CANCER; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; HUMAN; LABORATORY; SUPERFICIAL CANCER; TREATMENT OUTCOME;

EID: 0038346717     PISSN: 10236090     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kurth KH, Denis L, Bouffioux Ch et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 31A: 1840-6,
2. Schenkman CL, Lamm DL. Superficial bladder cancer therapy. Digital Urology Journal 2000. http://www.duj.com/article/Schenkman.html.
3. Traynelis CL, Lamm DL. Current status of intravesical therapy for bladder cancer. Urol Ann 1994; 8: 113-43.
4. Pawinski A, Bouffioux C, Sylvester SY et al. Metaanalysis of EORTC/MRC random mixed clinical trials for prophylactic treatment of Ta, T1 bladder cancer. J Urol 1996; 155: 492A (727).
5. Lamm DL, Griffith G, Pettit LL et al. Current perspective on diagnosis and treatment of superficial bladder cancer. Urology 1992; 39: 301-8.
6. Nadler RB, Catalona WJ, Hudson MA, Ratliff TL. Durability of tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol 1994; 152: 367-73.
7. Herr HW. Transurethral resection and intravesical therapy of superficial bladder tumors. Urol Clin North Am 1991; 18: 525-8.
8. Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573-80.
9. Lamm DL, Crissman J, Blumenstein B. Adriamycin versus BCG in superficial bladder cancer, a SWOG study. Prog Clin Biol Res 1989; 310: 263-70.
10. Mekelos MD, Chionis HS, Pavanychianakis GS et al. Intravesical 4′epi-doxorubicin (epirubicin) versus bacillus Calmette-Guerin. A controlled prospective study on the prophylaxis of superficial bladder cancer. Cancer 1993; 72: 1749-55.
11. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta T1 and carcinoma in situ transitional cell carcinoma of the bladder. A randomized Southwest Oncology Group study. J Urol 2000; 163: 1124-9.
12. Lamm DL, DeHaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol 2000; 37 (Suppl 3): 41-4.
13. Sylvester SY, van der Meijden APM, Lamm DL. Can BCG delay or prevent progression of superficial bladder cancer? J Urol 2002; 168: 1964-70.
14. Olsson CA, Chute R, Rao CN. Immunologic reduction of bladder cancer recurrence rate. J Urol 1974; 111: 173-6.
15. Lamm DL, Reyna JA, Reichert DF. Keyhole limpet hemocyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma. Urol Res 1981: 9: 227-30.
16. Jurincic CD, Engelmann U, Gasch J, Klippel KF. Immunotherapy in bladder cancer with keyhole limpet hemocyanin: a randomized study. J Urol 1988; 139: 723-6.
17. Flamm J, Bucher A, Höltl W et al. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy: A prospective randomized trial. J Urol 1990; 144: 260-3.
18. Lamm DL, Ebert RF, Hanna M et al. Keyhole limpet hemocyanin (KLH) immunotherapy of MBT-2 murine transitional cell carcinoma of the bladder. J Urol 1991; 145: 4.
19. Lamm DL, DeHaven JI, Riggs DR, Ebert RF. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH). J Urol 1993; 149: 648-52.
20. Lamm DL, DeHaven JI, Riggs DR et al. Immunotherapy of murine transitional cell carcinoma with Immuncothel, a modification of keyhole limpet hemocyanin (KLH). Urol Res 1993; 21:21-33.
21. Lamm DL, De Haven JI, Riggs DR et al. Keyhole limpet hemocyanin immunotherapy of murine bladder cancer. Urol Res 1993; 21: 33-7.
22. Lasmm DL, Morales A, Grossman HB et al. Keyhole limpet hemocyanin (KLH) immunotherapy of papillary and in situ transitional cell carcinoma of the bladder: A multicenter phase 1/11 clinical trial. J Urol 1996; 155: 1405-12.
23. Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 1985; 134: 40-7.
24. Herr HW, Pinsky CM, Whitemore WE et al. Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology 1985; 25: 119-24.
25. Herr HW, Laudone VP, Badalament RA et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450-5.
26. Yamamoto T, Hagiwara M, Nakazano M et al. Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer. Prospective randomized study for prophylactic effect. Japan J Urol 1990; 81: 997-1001.
27. Pagano F, Bassi P, Milani C et al. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: Is it effective? J Urol 1991; 146: 32-6.
28. Mekelos MD, Chionis H, Pantazakos A et al. Bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol 1993; 149: 744-52.
29. Krege S, Giani G, Meyer R et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J Urol 1996; 156: 926-66.